These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology.
    Author: Zinner RG, Saxman SB, Peng G, Monberg MJ, Ortuzar WI.
    Journal: Clin Lung Cancer; 2010 Sep 01; 11(5):352-7. PubMed ID: 20837462.
    Abstract:
    Herein we describe a companion ongoing randomized phase III study in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). Patients with chemotherapy-naive advanced disease will be randomized to receive either pemetrexed 500 mg/m2 plus carboplatin area under the curve (AUC) 6 for 4 cycles followed by maintenance pemetrexed (arm A) or paclitaxel 200 mg/m2 plus carboplatin AUC 6 plus bevacizumab 15 mg/kg for 4 cycles followed by maintenance bevacizumab (arm B). Cycles are 3 weeks. The primary endpoint is progression-free survival (PFS)without grade 4 toxicity (G4PFS) and will test the hypothesis that G4PFS is superior for the pemetrexed-containing combination. This type of endpoint has been used previously in clinical trials in which survival outcomes have been shown to be similar between treatment regimens; thus, a regimen that reduces the risk of toxicity is clinically relevant, particularly in the palliative setting. The study will enroll approximately 360 patients (180 per arm), allowing for a 10% drop-out. Assuming a hazard ratio (HR) of 0.75, this study will have an 80% statistical power to detect superiority of arm A over arm B with the use of a 1-sided log-rank test and a type I error of 0.05. If the true median G4PFS for arm B is 3 months, then the HR of 0.75 equals approximately 1 month of improvement in median G4PFS for arm A. A gatekeeper strategy will be used to sequentially test PFS. This strategy will preserve the overall type I error rate when conducting statistical tests on both G4PFS and PFS.
    [Abstract] [Full Text] [Related] [New Search]